Volunteer   |   About MSDC   |   Login
Melanoma: Biology & Patient Management 2018
Tell a Friend About This EventTell a Friend
 

10/13/2018
When: Saturday, October 13, 2018
Where: Omni Shoreham Hotel
2500 Calvert St NW
Washington, District of Columbia  20008
United States
Contact: Lauren Mazanec
lauren.a.mazanec@medstar.net
202-780-1619

« Go to Upcoming Event List  





Overview

This interdisciplinary, one-day conference will examine clinical updates in melanoma biology staging and early disease management. In addition, revolutionary advances in the treatment of patients with high risk and metastatic disease will be discussed with a special emphasis on the multidisciplinary approach in the care of melanoma patients. This will include new data on the role of completion lymph node dissections, adjuvant therapy, the management of patients with brain metastases, duration of therapy, toxicity management and the revised AJCC staging system and the impact of all of these factors on patient management. Case presentations and debates will address complex and controversial management issues in patients with high risk and advanced melanoma. Learn more or register online.

Course Co-Directors: Michael B. Atkins, MD; Waddah B. Al-Refaie, MD, FACS; Geoffrey T. Gibney, MD

Physician Objectives
  Analyze and apply new insights in the diagnosis and treatment of advanced melanoma.
  Apply the 8th edition of the AJCC staging system, utilize appropriate staging modalities to correctly gauge patient risk of recurrence and death and choose most appropriate patient care strategy.
  Review and apply NCCN, SITC and AJCC and other guidelines for the pre-operative evaluation of melanoma patients including the indications for radiographic studies, such as PET and CT scans.
  Recognize the value of multidisciplinary evaluation and assessment , in contributing to more effective and expedited patient treatment.
  Assess new data on molecularly targeted therapies and novel immunotherapy in order to develop integrated treatment plans for patients with various molecular subtypes and stages of disease.
  Incorporate salvage surgery and targeted radiation in selected patients to enhance long term outcomes.
  Recognize the changing role completion lymph node dissection.
  Describe the new Data on choice of combination vs. single agent immunotherapy.
  Apply new Data on adjuvant and neoadjuvant therapy.
  Recognize new approaches to the management of patients with brain metastases

Registration Fees
Physician $150
Resident/Fellow $50
Physician Assistant $75
Nurse Practitioner $75
Nurse $75
Allied Health Professional $75


This activity was planned by and for the healthcare team, and learners will receive 7.25 Interprofessional Continuing Education (IPCE) credits for learning and change.


Association Management Software Powered by YourMembership  ::  Legal